



## Consolidated Financial Results for the Fiscal Year Ended March 31, 2016 [Based on Japanese GAAP]

May 11, 2016

Name of Listed Company: Meiji Holdings Co., Ltd.      Listed exchange: 1st Section, Tokyo Stock Exchange  
 Code Number: 2269      URL: [www.meiji.com](http://www.meiji.com)  
 Representative: Masahiko Matsuo, President and Representative Director  
 Inquiries: Jun Furuta, Member of the Board and Executive Officer, General Manager of PR&IR Dept.  
 Telephone: +81-3-3273-3917

Annual shareholders meeting: June 29, 2016  
 Submission of the securities report: June 29, 2016  
 Dividend payment commencement: June 7, 2016  
 Preparation of explanatory materials for full-term financial results: Yes  
 Holding of a briefing on full-term financial results: Yes (a briefing for analysts and institutional investors)

(Amounts are rounded down to the nearest million yen.)

### 1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2016 (April 1, 2015 to March 31, 2016)

(1) Consolidated operating results (% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the fiscal year ended								
March 31, 2016	1,223,746	5.4	77,781	50.9	81,826	52.7	62,580	102.6
March 31, 2015	1,161,152	1.1	51,543	41.2	53,582	37.1	30,891	62.1

(Note) Comprehensive income: Fiscal year ended March 31, 2016: 47,750 million yen (-15.9%)  
 Fiscal year ended March 31, 2015: 56,757 million yen (110.7%)

	Net Income per Share	Diluted Net Income per Share	Return on Equity	Ordinary Income/Total Assets	Operating Income/Net Sales
For the fiscal year ended	Yen	Yen	%	%	%
March 31, 2016	425.06	—	16.1	9.4	6.4
March 31, 2015	209.79	—	8.9	6.5	4.4

(Reference) Equity in income of affiliates: Fiscal year ended March 31, 2016: 1,528 million yen  
 Fiscal year ended March 31, 2015: 376 million yen

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net income amounts for FYE March 2015 and FYE March 2016 reflect this stock split.

### (2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2016	856,115	419,152	47.8	2,777.28
As of March 31, 2015	877,367	380,302	42.2	2,515.26

(Reference) Shareholders' equity: As of March 31, 2016: 408,874 million yen  
 As of March 31, 2015: 370,341 million yen

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net assets amounts as of March 31, 2015 and March 31, 2016 reflect this stock split.

(3) Consolidated cash flows

	Cash Flows from Operating Activities	Cash Flows from Investing Activities	Cash Flows from Financing Activities	Cash and Cash Equivalents at Year-End
For the fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2016	105,155	-9,809	-85,071	31,516
March 31, 2015	86,487	-92,822	6,846	21,912

2. Dividends

	Cash Dividends Per Share					Total Cash Dividends (Annual)	Payout Ratio (Consolidated)	Dividends to Net Assets Ratio (Consolidated)
	1Q	2Q	3Q	Financial year end	Annual			
For the fiscal year ended (or ending)	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
March 31, 2015	—	40.00	—	60.00	100.00	7,362	23.8	2.1
March 31, 2016	—	55.00	—	62.50	—	13,250	21.2	3.4
March 31, 2017 (Projected)	—	45.00	—	45.00	90.00		26.5	

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share dividend amounts for FYE March 2015 and per-share interim dividend amount for FYE March 2016 do not reflect this stock split.

3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2017

(April 1, 2016 to March 31, 2017)

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income attributable to shareholders of parent company		Net Income per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
1st half	606,000	2.3	32,500	-2.7	32,500	-8.6	23,500	-29.1	159.62
Full year	1,251,000	2.2	74,500	-4.2	74,200	-9.3	50,000	-20.1	339.61

\*Notes

(1) Changes in significant subsidiaries during the current fiscal year under review

(Changes in subsidiaries affecting the scope of consolidation): Yes

Newly consolidated: —

Removed from scope of consolidation: 1 company (Meiji Seika (Shanghai) Co., Ltd.)

(2) Changes in accounting policy, changes in accounting estimates, restatements

1. Changes in accounting policy due to revisions of accounting standards: Yes

2. Other changes in accounting policy: Yes

3. Changes in accounting estimates: Yes

4. Restatements: None

(3) Number of shares outstanding (common stock)

1. Number of shares outstanding at end of period (including treasury stock)	As of Mar. 31, 2016	152,683,400shares	As of Mar. 31, 2015	152,683,400shares
2. Number of treasury stock at end of period	As of Mar. 31, 2016	5,462,223shares	As of Mar. 31, 2015	5,445,464shares
3. Average number of shares during period	As of Mar. 31, 2016	147,227,742shares	As of Mar. 31, 2015	147,249,538shares

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated number of shares outstanding (common stock) reflects this stock split.

**(Reference) Non-Consolidated Financial Results for Fiscal Year Ended March 31, 2016****(April 1, 2015 to March 31, 2016)**

(1) Non-consolidated operating results

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
For the fiscal year ended								
March 31, 2016	9,674	3.9	7,437	0.5	7,924	6.2	19,012	128.6
March 31, 2015	9,312	-0.3	7,397	-1.4	7,458	-9.2	8,315	6.8

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
For the fiscal year ended		
March 31, 2016	129.14	—
March 31, 2015	56.47	—

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net income amounts for FYE March 2015 and FYE March 2016 reflect this stock split.

(2) Non-consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2016	432,663	283,618	65.6	1,926.48
As of March 31, 2015	489,690	273,720	55.9	1,859.14

(Reference) Shareholders' equity: As of March 31, 2016: 283,618 million yen

As of March 31, 2015: 273,720 million yen

\* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net assets amounts as of March 31, 2015 and March 31, 2016 reflect this stock split.

&lt;Reasons for the year-on-year differences of non-consolidated results&gt;

Net income increased because gains on the sale of fixed assets were recorded as extraordinary income.

\* Indication regarding the implementation of financial review procedures

This financial results report is not subject to the review procedures prescribed by the Financial Instruments and Exchange Act. At the time of the disclosure of this financial results report, the review procedures prescribed by the Financial Instruments and Exchange Act had not been completed.

\* Forward-looking statements and other special notes

(Notice concerning forward-looking statements)

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of these materials and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved. For earnings forecasts assumptions and other related items, refer to page 1 of "1. Operating Results and Financial Position, (1) Analysis of Operating Results, (iii) Forecasts for the Fiscal Year ending March 31, 2017."

(Explanatory material for financial results)

Explanatory materials for financial results are disclosed through TDnet together with these financial statements. This information also is posted on our website on the same day.

## 1. Operating Results and Financial Position

### (1) Analysis of Operating Results

(Millions of yen)

For the fiscal year ended	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
March 31, 2016	1,223,746	77,781	81,826	62,580	425.06
March 31, 2015	1,161,152	51,543	53,582	30,891	209.79
% of YoY Change	5.4	50.9	52.7	102.6	—

The Japanese economy during the current consolidated fiscal year transitioned on a mild recovery trend thanks to improved corporate earnings. We also saw an improvement in the hiring and wage environment as well as an upward trend in consumer prices. On the other hand, growing concern about not only the state of overseas economies and currency markets but also about sentiment among domestic consumers has left us in an environment lacking clarity about the future.

Amid such conditions, the Meiji Group entered the inaugural year of STEP UP 17, the Group's Medium-Term Business Plan. Based on our core policy of accelerating growth and achieving further improvement in profitability, we launched the initiatives of our growth strategy aimed at increasing corporate value. These initiatives include strengthening priority businesses and taking on the challenge of future growth, improving profitability to withstand harsh economic environments, pursuing global expansion, and evolving our management system.

In the food segment, we conducted selection and concentration to expand sales of mainstay products and review unprofitable businesses in order to further strengthen priority businesses. In response to rising raw material procurement costs, we worked to optimize production and to reduce costs. Also, we increased prices for mainstay products.

In the pharmaceuticals segment, government policies to promote the generic drugs use are driving reductions in medical care spending. We responded by conducting marketing activities promoting our core domain, antibacterial drugs and CNS agents, and generic drugs. We identified cost competitiveness as a key issue and initiated production and procurement streamlining on a global level.

These factors resulted in net sales of 1,223,746 million yen (up 5.4%, year on year), operating income of 77,781 million yen (up 50.9%, year on year), ordinary income of 81,826 million yen (up 52.7%, year on year), and net income attributable to shareholders of parent company of 62,580 million yen (up 102.6%, year on year) during the fiscal year ended March 2016.

Beginning with the current consolidated fiscal year, we applied the Accounting Standard for Business Combination (ASBJ Statement No. 21, September 13, 2013), thereby changing "Net income" to "Net income attributable to shareholders of parent company".

Below is an overview by segment.

(Millions of yen)

	Reporting Segments			Adjustments	Amount Presented in Consolidated Statements of Income
	Food	Pharmaceuticals	Total		
Net Sales	1,061,398	164,542	1,225,940	-2,194	1,223,746
Operating Income	68,289	10,118	78,408	-626	77,781

(i) Food segment

(Millions of yen)

	For the Fiscal year ended March 31, 2015	For the Fiscal year ended March 31, 2016	% of YoY Change
Net Sales	1,021,806	1,061,398	3.9
Operating Income	41,664	68,289	63.9

Net sales increased year on year. Net sales of the fresh and fermented dairy business, confectionery business, and international business increased year on year. Net sales of nutritionals business increased significantly year on year. On the other hand, net sales of processed food business declined year on year.

Operating income increased significantly year on year. Increases in raw material procurement costs were compensated for with price hikes. In each business, efforts such as product mix improvements, production optimization, and other structural reforms were implemented along with the ones to improve the efficiency of cost expenditures.

Below is an overview of each of this segment's main businesses.

■ Fresh and Fermented Dairy business (Yogurt, drinking milk, beverages, etc.)

- Net sales of functional yogurt increased significantly year on year. Net sales of *Meiji Probio Yogurt R-1* increased significantly year on year. The new flavors of *Meiji Probio Yogurt R-1* released in October and November of 2015 contributed to sales. *Meiji Probio Yogurt PA-3*, released in April 2015, recorded net sales that outperformed initial sales targets.
- Net sales of *Meiji Bulgaria Yogurt* increased year on year. Net sales of our mainstay Plain yogurt drove overall brand sales thanks to increased interest in the health value of yogurt and expanded consumption opportunities resulting from the diversification of eating styles. Net sales of the drinkable yogurt products also continued strong growth thanks to the increased our product lineup.
- Net sales of drinking milk increased year on year. The entire lineup for our mainstay product *Meiji Oishii Gyunyu* increased year on year. This was the result of continuous efforts to promote the product as an ingredient for cooking.

■ Processed Food business (Cheese, butter and margarine, cream, ice cream, frozen food, etc.)

- Net sales of cheese increased year on year. Natural cheese increased significantly year on year thanks to the strong sales of camembert cheese. Processed cheese increased year on year due to favorable sales of sliced cheese.
- Net sales of margarine decreased year on year due to the market decline.
- Net sales of ice cream increased year on year. Net sales of our mainstay products *Meiji Essel Super Cup* series were favorable. Net sales of the *Meiji Gold Line* series increased significantly year on year due to launch of new products.

■ Confectionery business (Chocolate, gummy, chewing gum, etc.)

- Net sales of chocolate increased year on year. Net sales of the *Chocolate Kouka* series increased significantly year on year thanks to increased interest in cocoa polyphenols and cocoa protein. Net sales of the *Galbo* series increased significantly year on year thanks to new products in the series.
- Net sales of gummy products significantly increased year on year. Our mainstay brand *Kaju Gummy* and *Poifull* grew significantly.
- Net sales of gum decreased year on year due to the declining market.

■ Nutritionals business (Sports nutrition, infant formula, enteral formula, beauty supplement, OTC drugs, etc.)

- Net sales of sports nutritionals increased significantly year on year. Net sales of *SAVAS* increased significantly year on year. In addition to seeing the benefits of years of promotional activities targeting athletes, we captured more of the market for new protein users whose interests revolve around building a healthy body. Net sales of *VAAM* increased significantly year on year due to continued promotional activities and expanded sales routes.
- Net sales of infant formula increased significantly year on year due to increased inbound demand.
- Net sales of enteral formula increased significantly year on year. In particular, net sales of *Meiji Mei Balance Mini Cups* for the consumer market increased significantly thanks to increased consumer awareness of the

importance of senior nutrition and due to growing product recognition.

- In the beauty supplement, net sales of *Amino Collagen* increased significantly year on year due to increased inbound demand.

■ Other business (Overseas, food stuffs, livestock products, sugar and corn sweeteners, transportation, etc.)

Overseas

- Among exports, net sales of chocolate snacks to Thailand and Hong Kong, and *Amino Collagen* increased significantly year on year. Sales of infant formula for the growing Pakistan market increased significantly year on year.
- Net sales in China increased significantly year on year. In the confectionery business, sales of chocolate for wedding gift and export to Southeast Asia both grew. The drinking milk and yogurt business released new products and expand its sales area. The ice cream business launched full-scale production in January 2015.
- Net sales in the U.S.A. increased significantly year on year. Sales of *Hello Panda*, *Chocorooms* (U.S.A. version of the chocolate snack, *Kinoko no Yama*), and other chocolate snacks were favorable.

Others

- Net sales at domestic subsidiaries increased year on year due to expansion of the distribution business.

(ii) Pharmaceuticals segment

(Millions of yen)

	For the Fiscal year ended March 31, 2015	For the Fiscal year ended March 31, 2016	% of YoY Change
Net Sales	141,338	164,542	16.4
Operating Income	10,076	10,118	0.4

Net sales increased significantly year on year. In the domestic ethical pharmaceuticals business, net sales of brand name drugs increased year on year and net sales of generic drugs increased significantly year on year. Net sales in the agricultural chemicals and veterinary drugs business increased significantly year on year due to a significant increase in revenues from mainstay products. Net sales for overseas business increased significantly year on year. Exports of mainstay products were favorable. Medreich, which became a consolidated subsidiary in the fourth quarter of the previous fiscal year, contributed to sales.

Operating income increased year on year despite the adverse effect of one-time revenues from licensing agreements executed during the previous year. In addition to increased revenues, operating income also benefitted from initiatives related to low-cost operations in domestic and foreign production sites.

Below is an overview of each of this segment's main businesses.

■ Ethical Pharmaceuticals

Japan

- Net sales of the antibacterial drug *MEIACT* decline year on year due to the replacement by the generic Cefditoren Pivoxil. Net sales of *ORAPENAM* increased significantly year on year.
- Net sales of the antidepressant drug *REFLEX* increased significantly year on year due to aggressive promotional activities by medical representatives.
- Net sales of generic drugs increased significantly year on year. Our mainstay calcium channel blocker, *AMLODIPINE Tablets Meiji* and the antibacterial drug *SULBACILLIN for Injection Meiji* performed favorably. The antibacterial drug *TAZOPIPE Combination for I.V. Infusion Meiji* released in December 2015 and the antidepressant drug *SERTRALINE Meiji* also contributed to sales growth.

Overseas

- Among exports, net sales of our mainstay *MEIACT* increased significantly year on year.
- Among overseas subsidiaries, in addition to sales from Medreich, businesses in Indonesia and Thailand increased significantly year on year.

■ Agricultural chemicals and veterinary drugs

- Net sales of agricultural chemicals increased significantly year on year. Sales of rice blast preventative *ORYZEMATE* and herbicide *ZAXA* increased year on year.
- Net sales of veterinary drugs increased year on year. Net sales of livestock drugs increased year on year, and

drugs for companion animals increased significantly year on year. Net sales of marine chemicals decreased year on year.

(iii) Forecasts for the Fiscal Year ending March 31, 2017

Our consolidated earnings forecast for FY2016 (period ending March 2017) are net sales of 1,251,000 million yen, operating income of 74,500 million yen, ordinary income of 74,200 million yen, and 50,000 million yen as profit attributable to shareholders of parent company.

(Millions of yen)

For the fiscal year ended (or ending)	Net Sales	Operating Income	Ordinary Income	Net Income attributable to shareholders of parent company	Net Income per Share (Yen)
March 31, 2017 (Forecasts)	1,251,000	74,500	74,200	50,000	339.61
March 31, 2016 (Results)	1,223,746	77,781	81,826	62,580	425.06
% of YoY Change	2.2	-4.2	-9.3	-20.1	—

Below is an overview by segment.

(Millions of yen)

	Reporting Segments			Adjustments	Amount Presented in Consolidated Statements of Income
	Food	Pharmaceuticals	Total		
Net Sales	1,073,000	179,800	1,252,800	-1,800	1,251,000
% of YoY Change	1.1	9.3	2.2	—	2.2
Operating Income	65,000	10,000	75,000	-500	74,500
% of YoY Change	-4.8	-1.2	-4.3	—	-4.2

■ Food segment

The food industry faces the urgent need of initiatives to address advancing domestic population decline, population aging, and low birth rates, medium- to long-term measures to address imported raw materials procurement and pricing, and initiatives related to food safety and reassurance.

Amid such an environment, in the food segment we will expand our share in our core product categories, achieve continuous cost reductions and business structure reforms, and strengthen our quality assurance system.

Fresh and Fermented Dairy business (Yogurt, drinking milk, beverages, etc.)

For probiotics yogurt, we will increase sales of *Meiji Probio Yogurt R-1*, *Meiji Probio Yogurt LG21*, and *Meiji Probio Yogurt PA-3*. For yogurt, we will propose new value and expand drinkable yogurt products to achieve the continued growth of the *Meiji Bulgaria Yogurt* brand. For drinking milk, we will continue aggressive advertising campaigns for *Meiji Oishi Gyunyu* and increase brand recognition.

Processed Food business (Cheese, butter and margarine, cream, ice cream, frozen food, etc.)

For cheese for consumer market, we will enhance the product marketing of the *Meiji Hokkaido Tokachi* series and expand sales. For ice cream, we will expand sales of the *Meiji Essel Super Cup* and the *Meiji Gold Line*.

Confectionery business (Chocolate, gummy, chewing gum, etc.)

For chocolate, we will strengthen the market image of “Meiji for chocolate” as part of our commemoration of the 90<sup>th</sup> anniversary since the launch of *Meiji Milk Chocolate*. We will work aggressively to permeate the value of premium chocolate and promote the health value of cocoa for *Chocolate Kouka* series.

Also, we will expand sales of *Kaju Gummy*, and strengthen the *Xylish* brand.

### Nutritionals business (Sports nutrition, infant formula, enteral formula, beauty supplement, OTC drugs, etc.)

For sports nutritionals, we will promote the *VAAM* and *SAVAS* to capture new consumers and use an aggressive advertising campaign to establish a solid market presence and strengthen the brand. For infant formula, we will strengthen our promotion of nutritional value and expand the *Rakuraku Cube* amid a **domestic market that is shrinking due to declining birth rates**. For enteral formulas, we will increase sales of consumer products in a growing market.

### Other business (Overseas, food stuffs, livestock products, sugar and corn sweeteners, transportation, etc.)

#### Overseas

We will enhance marketing efforts using mainstay products in core areas such as China, Asia, and the U.S.A., and work aggressively to expand business and improve profitability.

#### Others

For domestic affiliates, we will advance structural reforms to improve further profitability. We will offer unique value to contribute to overall Group expansion.

### ■ Pharmaceuticals segment

The market conditions of the domestic pharmaceuticals industry have changed greatly amid additional price cut on long-term list drugs, the promotion of generic drugs, and other measures implemented by the government towards controlling national medical expenditures.

Amid such an environment, for the pharmaceuticals segment we will increase our presence in core domains and expand into new domains in order to achieve continuous growth as a Specialty and Generic Pharmaceuticals Company. We will expand initiatives related to low-cost operations in domestic and foreign production sites. We also foster growth of overseas subsidiaries to promote global expansion.

### Ethical Pharmaceuticals

#### Japan

We will improve our competitive advantages in the field of infectious diseases, central nervous system (CNS) disorders, and generic pharmaceuticals. We will minimize the impact of drug price revisions and secure profits through the release of the schizophrenia drug *SYCREST* and the anti-allergy drug TAC-202 (generic name: bilastine).

#### Overseas

Overseas subsidiaries will expand sales locally and in neighboring countries. Medreich in India will achieve continued growth in CMO and CDMO business and the production and sales of generic drugs. Also, the company will establish a production system for drug exports to Japan.

### Agricultural chemicals and veterinary drugs

For agricultural chemicals, we will distinguish ourselves from competitors by expanding sales of rice blast preventative *ORYZEMATE* and herbicide *ZAXA*. For veterinary drugs, we will increase sales efficiency and expand sales by reducing low profitable products.

## (2) Qualitative Information Concerning Financial Position

### (i) Assets, Liabilities, and Net Assets

#### [Assets]

Total assets as of the end of the current consolidated fiscal year decreased year by year by 21,251 million to 856,115 million yen. Although cash and deposits increased by 9,394 million yen, retirement benefit assets and investments and other fixed assets decreased by 14,155 million yen and 14,568 million yen respectively.

#### [Liabilities]

Total liabilities as of the end of the current consolidated fiscal year decreased year by year by 60,102 million to 436,963 million yen. Although income taxes payable increased by 10,677 million yen, short-term bank loans, commercial paper, and current portion of bonds decreased by 19,759 million yen, 38,000 million yen, and 15,000 million yen, respectively.

#### [Net Assets]

Total net assets as of the end of the current consolidated fiscal year increased year by year by 38,850 million to 419,152 million yen. Although foreign currency translation adjustments and adjusted cumulative of retirement benefits decreased by 4,421 million yen and 10,623 million yen, respectively, retained earnings increased by 54,702 million yen.



The equity ratio as of the end of the current consolidated fiscal year increased from 42.2% to 47.8% and net assets per share increased from 2,515.26 yen as of the end of the previous consolidated fiscal year to 2,777.28 yen.

(ii) Cash Flows

(Millions of yen)

	For the Fiscal year ended March 31, 2015	For the Fiscal year ended March 31, 2016	Change
Net cash flow from operating activities	86,487	105,155	18,668
Net cash flow from investing activities	-92,822	-9,809	83,013
Net cash flow from financing activities	6,846	-85,071	-91,917
Translation adjustment on cash and cash equivalents	668	-669	-1,337
Net increase (decrease) in cash and cash equivalents	1,179	9,605	8,425
Cash and cash equivalents at beginning of year	19,238	21,912	2,673
Increase in cash and cash equivalents from newly consolidated subsidiary	1,494	-	-1,494
Decrease in cash and cash equivalents incidental to exclusion from consolidation	-	-1	-1
Cash and cash equivalents at end of period	21,912	31,516	9,603

Cash flow from operating activities resulted in revenues of 105,155 million yen, an increase of 18,668 million yen compared to the previous consolidated fiscal period. This was due to an increase in income before income taxes and minority interests and a decrease in inventories.

Cash flow from investing activities decreased by 83,013 million yen compared to the end of the previous consolidated fiscal year to 9,809 million yen. This was due to increased income from the sale of investment real estate, which exceeded the impact of expenditures due to the acquisition of fixed tangible assets. As a result, free cash flow (total of cash flow from operating activities and cash flow from investing activities) resulted in revenues of 95,346 million yen, an increase in revenues of 101,681 million yen compared to the previous consolidated fiscal period.

Cash flow from financing activities resulted in expenditures of 85,071 million yen, a 91,917 million yen increase in expenditures compared to the previous consolidated fiscal period. This was the result of expenditures related to bond redemption and the reduction of commercial paper obligations.

As a result, cash and cash equivalents as of the end of the current consolidated fiscal period was 31,516 million yen.

Cash flow indices were as follows.

	3rd accounting year (ended March 31, 2012)	4th accounting year (ended March 31, 2013)	5th accounting year (ended March 31, 2014)	6th accounting year (ended March 31, 2015)	7th accounting year (ended March 31, 2016)
Equity ratio (%)	38.9	39.9	41.1	42.2	47.8
Equity ratio on market price basis (%)	35.5	40.9	61.5	122.9	155.6
Debt repayment period	6.7	4.1	3.1	2.6	1.4
Interest coverage ratio	15.0	29.5	48.6	76.2	104.1

Note: How to calculate each index is as below.

Equity ratio: (net assets - non-controlling interests) / Total assets

Equity ratio on market price basis: Total market value of shares (Closing share price at end of period × total no. of shares issued) / Total assets

Debt repayment period: Interest-bearing debt (bonds, borrowings, commercial paper) / Cash flow from operating activities

Interest coverage ratio: Cash flow from operating activities / Interest payments (amount of interest payments)

\* Forward-looking statements and other special notes

The above forecasts are based on information currently available at the time of the release of this report and reasonable assumptions made by the Company. Actual results could differ materially from forecasts due to various factors.

(3) Basic policy concerning income dividends and dividends for the current and upcoming fiscal periods

Meiji Holdings contributes to the lifelong health and food lifestyles of our customers. Securing the medium and long-term stability of our operating platform is vital.

It is important to ensure the internal retention necessary for future capital investments, investment and financing capital, R&D investments, etc., while enabling stable, sustainable profit returns for shareholders. Our basic policy concerning profit dividends shall be consolidated dividend payout ratio of around 30%. If the extraordinary factors influence on net income significantly, that influence may be removed from the determination of the dividend amount.

We conducted a two-for-one stock split of common stock on October 1, 2015. The dividend as of the end of the second quarter is 55.00 yen per share (pre-split). The dividend as of the end of the fiscal period is 62.50 yen per share (post-split). The annual dividend for the current fiscal period is 90.00 yen per share (if calculated on post-stock split basis), and 180.00 yen (if calculated on pre-stock split basis). This result in a consolidated dividend payout ratio is 21.2%.

As indicated in the “Notice Concerning the Transfer of Fixed Assets and Reporting of Extraordinary Profits” issued on March 10, 2015, we recorded extraordinary income during the current fiscal period. As a result, the consolidated dividend payout ratio becomes 25.8% when the effect of said nonrecurring special factors is excluded in accordance with the abovementioned basic policy.

For the annual dividend for the upcoming fiscal period, we are planning a dividend of 90.00 yen (45.00 yen at end of second quarter and 45.00 yen at end of fiscal period), and forecasting a dividend payout ratio of 26.5%.

## 2. Management Policy

### (1) Basic Policies of Company Management

We work relentlessly to help improve the lifestyles of customers across all generations in the “Food and Healthcare” domains, and are targeting growth and advancement as a world-renowned corporate group, while working to continually enhance value for customers, shareholders and other stakeholders.

#### 1) Group Philosophy

Our mission is to widen the world of “Tastiness and Enjoyment” and meet all expectations regarding “Health and Reassurance.”

Our wish is to be closely in tune with our customers’ feelings and to always be there to brighten their daily lives.

Our responsibility as “Food and Health” professionals is to continue finding innovative ways to meet our customers’ needs, today and tomorrow.

#### 2) Group Philosophy

##### Five Fundamentals

1. Commit ourselves to customer-based ideas and behaviors
2. Provide safe and reassuring high-quality products
3. Strive to always produce new value
4. Foster the development of the synergies and capabilities of the organization and each individual
5. Be a transparent, wholesome company trusted by the society

### (2) Medium to long-term corporate management strategy

Amid a rapidly changing business environment on both domestic and international markets, in September 2010 we announced our 2020 Vision as a plan for the sustainable growth and development of the Meiji Group.

The 2020 Vision identifies our ideal Group image in FY2020 as "a corporate group that brightens customers' daily lives by providing customers of all ages, from infants to the elderly, with foods that offer tastiness and enjoyment, as well as products that contribute to customers' physical and emotional well-being."

As part of our 2020 Vision, we outlined STEP UP 17, our Group’s Medium-Term Business Plan for fiscal years 2015 through 2017 as a follow-up to TAKE OFF 14, our Group’s Medium-Term Business Plan for fiscal years 2012 through 2014. We launched the initiatives outlined in STEP UP 17 beginning in April 2015.

STEP UP 17 identifies the acceleration of growth and further improvement in profitability as core themes and aims to strengthen priority businesses and take on the challenge of new growth, achieve stronger profitability capable of withstanding changes in the harsh economic environment, pursue global expansion, and evolve our management system.

Benchmarks outlined for the final year of the plan are net sales of 1.26 trillion yen, operating income of 64 billion yen, and an ROE of 8% or higher.

Through diligent efforts towards achieving these targets, during the first year of the plan operating income and ROE for the fiscal period significantly exceeded targets, resulting in goal achievement ahead of schedule. We will not change the core themes or basic policies of STEP UP 17 but continue our efforts towards securing stable growth and development.

Details on 2020 Vision and STEP UP 17 are available via the following URL.

(Meiji website) <http://www.meiji.com/investor/index.html>

## 3. Fundamental approach to the selection of accounting practices

Many of the Meiji Group stakeholders are stockholders, creditors, and business partners located in Japan and the Group has only minimal need for capital procurement from overseas sources. Thus, at present we believe the application of Japanese standards is appropriate. For the foreseeable future, consolidated financial standards are created based on Japanese standards.

#### 4. Consolidated Financial Statements

##### (1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2015	As of March 31, 2016
<b>ASSETS</b>		
Current assets		
Cash and deposits	22,489	31,883
Notes and accounts receivable	172,762	181,493
Goods and products	82,799	80,729
Work in process	4,022	3,365
Raw materials and supplies	43,228	39,509
Deferred tax assets	10,290	9,387
Others	16,737	16,973
Allowance for doubtful accounts	-311	-423
Total current assets	352,018	362,919
Fixed assets		
Property, plants and equipment		
Buildings and structures	293,533	292,439
Less accumulated depreciation	-162,492	-166,333
Buildings and structures (net)	131,041	126,106
Machinery and equipment	481,470	495,891
Less accumulated depreciation	-353,849	-367,186
Machinery and equipment (net)	127,620	128,705
Tools and furniture	52,966	52,076
Less accumulated depreciation	-44,401	-43,161
Tools and furniture (net)	8,565	8,915
Land	71,036	72,837
Lease assets	7,033	4,833
Less accumulated depreciation	-4,500	-3,605
Lease assets (net)	2,532	1,228
Construction in progress	12,248	11,522
Total property, plants and equipment	353,044	349,314
Intangible assets		
Goodwill	23,323	14,560
Other	8,387	14,539
Total intangible assets	31,711	29,100
Investments and other fixed assets		
Investment securities	79,171	80,234
Retirement benefit assets	32,743	18,588
Deferred tax assets	4,798	6,614
Other	24,095	9,527
Allowance for doubtful accounts	-215	-183
Total investments and other fixed assets	140,593	114,781
Total fixed assets	525,349	493,196
Total assets	877,367	856,115

(Millions of yen)

	As of March 31, 2015	As of March 31, 2016
<b>LIABILITIES</b>		
Current liabilities		
Notes and accounts payable	104,279	104,006
Short-term bank loans	49,590	29,831
Current portion of bonds	-	20,000
Commercial paper	38,000	-
Accrued expenses	43,572	48,199
Income taxes payable	14,413	25,090
Accrued bonuses for employees	9,789	10,233
Allowance for sales returns	208	207
Allowance for sales rebates	1,803	1,892
Other current liabilities	36,918	37,235
Total current liabilities	298,575	276,696
Long-term liabilities		
Bonds	65,000	30,000
Long-term debt	68,889	67,997
Deferred tax liabilities	15,026	9,746
Retirement benefit liabilities	43,950	49,029
Reserve for directors' retirement benefits	215	161
Other long-term liabilities	5,406	3,331
Total long-term liabilities	198,489	160,266
Total liabilities	497,065	436,963
<b>NET ASSETS</b>		
Shareholders' equity		
Common stock	30,000	30,000
Capital surplus	98,853	98,502
Retained earnings	223,166	277,869
Treasury stock, at cost	-9,577	-9,727
Total shareholders' equity	342,442	396,645
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities	26,965	26,417
Deferred gains or losses on hedges	85	8
Foreign currency translation adjustments	7,558	3,137
Adjusted cumulative of retirement benefits	-6,711	-17,334
Total accumulated other comprehensive income	27,898	12,229
Minority interests	9,961	10,278
Total net assets	380,302	419,152
Total liabilities and net assets	877,367	856,115

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income  
(Consolidated Statements of Income)

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
Net sales	1,161,152	1,223,746
Cost of sales	757,766	778,184
Gross profit	403,386	445,561
Selling, general and administrative expenses	351,842	367,780
Operating income	51,543	77,781
Non-operating income		
Interest income	96	153
Dividend income	1,010	2,274
Rent income on fixed assets	2,479	269
Foreign exchange gains	1,237	-
Equity in income of affiliates	376	1,528
Factory construction subsidy income	-	1,000
Other	1,818	1,931
Total non-operating income	7,019	7,157
Non-operating expenses		
Interest expenses	1,116	983
Rent cost of real estate	1,885	116
Foreign exchange losses	-	660
Loss from redemption of bonds	805	373
Other	1,173	979
Total non-operating expenses	4,980	3,112
Ordinary income	53,582	81,826
Extraordinary income		
Gain on sale of property, plants and equipment	1,844	19,761
Gain on sales of investment securities	699	72
Other	278	620
Total extraordinary income	2,821	20,454
Extraordinary losses		
Loss on disposal of property, plants and equipment	3,217	3,427
Impairment loss	3,623	1,859
Loss on valuation of investment securities	1	905
Other	904	877
Total extraordinary losses	7,747	7,069
Income before income taxes	48,657	95,210
Income taxes-current	20,633	35,311
Income taxes-deferred	-3,448	-3,704
Income taxes-total	17,184	31,606
Net income	31,473	63,604
Net income or net losses attributable to non-controlling shareholders	582	1,023
Net income attributable to shareholders of parent company	30,891	62,580

## (Consolidated Statements of Comprehensive Income)

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
Net income	31,473	63,604
Other comprehensive income		
Net unrealized holding gains or losses on securities	11,398	-553
Deferred gains or losses on hedges	142	-77
Foreign currency translation adjustments	4,812	-4,702
Adjustments related to retirement benefits	8,676	-10,626
Equity in affiliates accounted for by equity method	254	107
Total other comprehensive income	25,284	-15,853
Comprehensive income	56,757	47,750
(Breakdown)		
Comprehensive income attributable to shareholders of parent company	55,959	46,911
Comprehensive income attributable to minority shareholders	797	838

## (3) Consolidated Statements of Changes in Net Assets

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
<b>Shareholders' equity</b>		
Common stock		
Balance at the end of previous period	30,000	30,000
Changes during the period		
Total changes during the period	-	-
Balance at the end of current period	30,000	30,000
Additional paid-in capital		
Balance at the end of previous period	98,852	98,853
Changes during the period		
Disposal of treasury stock	0	2
Change in treasury shares of parent arising from transactions with non-controlling shareholders		-353
Total changes during the period	0	-350
Balance at the end of current period	98,853	98,502
Retained earnings		
Balance at the end of previous period	198,957	223,166
Changes during the period		
Cumulative effect due to change of accounting practices	-791	
Cash dividends	-5,890	-8,465
Net income attributable to shareholders of parent company	30,891	62,580
Increase by corporate division		5
Change of scope of consolidation		582
Total changes during the period	24,210	54,702
Balance at the end of current period	223,166	277,869
Treasury stock		
Balance at the end of previous period	-9,451	-9,577
Changes during the period		
Acquisition of treasury stock	-125	-150
Disposal of treasury stock	0	0
Total changes during the period	-125	-149
Balance at the end of current period	-9,577	-9,727
Total shareholders' equity		
Balance at the end of previous period	318,358	372,442
Changes during the period		
Cumulative effect due to change of accounting practices	-791	
Cash dividends	-5,890	-8,465
Net income attributable to shareholders of parent company	30,891	62,580
Acquisition of treasury stock	-125	-150
Disposal of treasury stock	1	3
Increase by corporate division		5
Change of scope of consolidation		582
Change in treasury shares of parent arising from transactions with non-controlling shareholders		-353
Total changes during the period	24,085	54,202
Balance at the end of current period	342,442	396,645



(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
<b>Accumulated other comprehensive income</b>		
Net unrealized holding gains or losses on securities		
Balance at the end of previous period	15,610	26,965
Changes during the period		
Net changes in items other than those in shareholders' equity	11,354	-547
Total changes during the period	11,354	-547
Balance at the end of current period	26,965	26,417
Deferred gains or losses on hedges		
Balance at the end of previous period	-57	85
Changes during the period		
Net changes in items other than those in shareholders' equity	142	-77
Total changes during the period	142	-77
Balance at the end of current period	85	8
Foreign currency translation adjustments		
Balance at the end of previous period	1,922	7,558
Changes during the period		
Net changes in items other than those in shareholders' equity	5,636	-4,421
Total changes during the period	5,636	-4,421
Balance at the end of current period	7,558	3,137
Total adjusted cumulative of retirement benefits		
Balance at the end of previous period	-15,386	-6,711
Changes during the period		
Net changes in items other than those in shareholders' equity	8,675	-10,623
Total changes during the period	8,675	-10,623
Balance at the end of current period	-6,711	-17,334
Total accumulated other comprehensive income		
Balance at the end of previous period	2,089	27,898
Changes during the period		
Net changes in items other than those in shareholders' equity	25,808	-15,669
Total changes during the period	25,808	-15,669
Balance at the end of current period	27,898	12,229
<b>Minority interests</b>		
Balance at the end of previous period	7,674	9,961
Changes during the period		
Net changes in items other than those in shareholders' equity	2,287	316
Total changes during the period	2,287	316
Balance at the end of current period	9,961	10,278

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
<b>Total net assets</b>		
Balance at the end of previous period	328,121	380,302
Changes during the period		
Cumulative effect due to change of accounting practices	-791	
Cash dividends	-5,890	-8,465
Net income attributable to shareholders of parent company	30,891	62,580
Acquisition of treasury stock	-125	-150
Disposal of treasury stock	1	3
Increase by corporate division		5
Change of scope of consolidation		582
Change in treasury shares of parent arising from transactions with non-controlling shareholders		-353
Net changes in items other than those in shareholders' equity	28,095	-15,352
Total changes during the period	52,972	38,850
Balance at the end of current period	380,302	419,152

## (4) Consolidated Statements of Cash Flow

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
Cash flows from operating activities		
Income before income taxes	48,657	95,210
Depreciation and amortization	41,885	42,077
Impairment loss	3,623	1,859
Amortization of goodwill	634	1,777
Loss on disposal of property, plants and equipment	3,199	3,414
Loss (gain) on valuation of investment securities	1	905
Increase (decrease) in allowance for doubtful accounts	-58	24
Increase (decrease) in accrued bonuses to employees	238	418
Increase (decrease) in retirement benefit liabilities	8,300	4,141
Interest and dividends received	-1,106	-2,427
Interest expenses	1,116	983
Equity in loss (income) of equity-method affiliates	-376	-1,528
Loss (gain) on sale of property, plants or equipment	-1,699	-19,707
Loss (gain) on sale of investment securities	-695	-71
Decrease (increase) in trade receivables	-3,405	-8,988
Decrease (increase) in inventories	-3,117	5,329
Increase (decrease) in trade payables	3,548	-673
Others	3,835	4,359
Subtotal	104,580	127,104
Interest and dividends received	1,107	2,824
Interest expenses paid	-1,135	-1,009
Income taxes paid	-18,065	-23,763
Net cash provided by operating activities	86,487	105,155
Cash flows from financing activities		
Payments for purchases of property, plants or equipment	-62,152	-40,078
Payments for purchases of intangible fixed assets	-2,194	-2,276
Proceeds from sales of property, plants or equipment and intangible fixed assets	4,330	2,352
Payments for investments in real estate	-2	-
Proceeds from sales of investments in real estate	-	33,918
Payments for purchases of investment securities	-2,563	-6,286
Proceeds from sales of investment securities	775	119
Proceeds from redemption of investment securities	-	3,500
Proceeds from sale of subsidiaries due to change in consolidated scope	-	1,273
Payments for sales of investments in subsidiaries resulting in change in scope of consolidation	-31,271	-466
Others	255	-1,885
Net cash used in investing activities	-92,822	-9,809

(Millions of yen)

	For the fiscal year ended March 31, 2015	For the fiscal year ended March 31, 2016
Cash flows from financing activities		
Increase (decrease) in short-term bank loans	-196	-19,084
Increase (decrease) in commercial paper	18,000	-38,000
Proceeds from long-term loans payable	34,685	2,501
Repayment of long-term loans payable	-2,228	-4,550
Redemption of bonds	-35,805	-15,373
Decrease (increase) in treasury stock	-124	-147
Cash dividends paid	-5,874	-8,441
Cash dividends paid to non-controlling shareholders	-97	-113
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	-	-416
Others	-1,513	-1,446
Net cash used in financing activities	6,846	-85,071
Translation adjustment on cash and cash equivalents	668	-669
Net increase (decrease) in cash and cash equivalents	1,179	9,605
Cash and cash equivalents at beginning of year	19,238	21,912
Increase in cash and cash equivalents from newly consolidated subsidiary	1,494	-
Decrease in cash and cash equivalents resulting from exclusion of subsidiaries from consolidation	-	-1
Cash and cash equivalents at end of period	21,912	31,516

## (5) Notes Concerning Consolidated Financial Statements

(Notes Concerning the Premise of a Going Concern)

Not applicable.

(Changes in Significant Matters That Constitute the Basis for Preparation of Consolidated Financial Statements)

(Change in scope of consolidation)

A company newly included into scope of consolidation as materiality increased: One

Medreich New Zealand Limited

A company included in scope of consolidation due to additional acquisition of stock: One

Tochigi Meiji Milk Products Co., Ltd.

Excluded from scope of consolidation due to completion of liquidation: One

Meiji Seika (Shanghai) Co., Ltd.

Excluded from scope of consolidation due to transfer of stock: One

Français Co., Ltd.

(Important changes in scope of application of the equity method)

Included in scope of equity method application due to acquisition of stock: One

DMB Limited

Included in scope of application of equity method due to increase in importance and then included in scope of consolidation due to additional acquisition of stock, which resulted in exclusion from scope of application of equity method: One

Tochigi Meiji Milk Products Co., Ltd.

(Changes in Accounting Policy)

Application of accounting standards related to business combination

Beginning with the current consolidated fiscal period, the Group adopted the provisions of the Accounting Standards for Corporate Combination (ASBJ Statement No. 21, September 13, 2013), the Accounting Standards for Consolidated Financial Statements (ASBJ Statement No. 22, September 13, 2013), and the Accounting Standards for Business Divestitures (ASBJ Statement No. 7, September 13, 2013). As a result of this change in accounting policy, differences resulting from the changes in Group holdings in subsidiaries remaining under Group control are recorded as capital surplus and expenses related to acquisition are recorded as expenses for the consolidated accounting period in which they were incurred. The accounting standard for business combination occurring after the beginning of the current consolidated fiscal year was changed to a method that reflects a review of the distribution of acquisition costs based on the finalization of provisional accounting treatments onto the consolidated financial statements for the consolidated accounting period in which the business combination date occurs. Furthermore, we changed how net income is represented and changed from an indication of minority interests to an indication of non-controlling interests.

“Proceeds from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation” and “**Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation**” are shown in Cash flows from financing activities of Consolidated Statements of Cash Flow of fiscal year ended March 2016.

The application of the Accounting Standard for Business Combination is subject to transitional treatment as outlined in Accounting Standard for Business Combination Paragraph 58-2 (4), Accounting Standard for Consolidated Financial Statements Paragraph 44-5 (4), and Accounting Standard for Business Divestitures Paragraph 57-4 (4). As such, the application of these standards is implemented from the start of the current consolidated fiscal year.

As a result, additional paid in capital as of the end of the current consolidated fiscal year decreased by 353 million yen. The impact of these changes on income is expected to be minor.

Furthermore, the impact on per share net assets and per share net income is minor.

(Changes in Accounting Policies to be distinguished from Changes in Accounting Estimates)

Change in depreciation method for depreciable assets

Previously, the declining-balance method of accounting was used to calculate the depreciation of tangible fixed assets belonging to Meiji Seika Pharma, which operates in the ethical pharmaceuticals segment, and its domestic subsidiaries. However, this was changed to the straight-line method beginning with the current consolidated fiscal year.

In STEP UP 2017, our Medium-Term Business Plan launched this fiscal year, the Specialty & Generics strategy outlines the Meiji Seika Pharma Group goal of enhancing our lineup of generic pharmaceuticals in order to further strengthen our business foundation and further increase sales of generic drugs. Domestic production facilities originally operated with a focus on Meiji original brand name drugs, but amid a trend towards reduced production of brand name drugs, the Group is planning to incorporate major generic drugs as a production resource.

A review of operating status at domestic production facilities indicated that more long-term stable operation could be expected. As such, it was determined that leveled depreciation via the straight-line method was the cost distribution method that appropriately reflected the operating status of these assets.

As a result of this change, operating income, ordinary income, and income before taxes and minority interests for the current consolidated fiscal year each increased by 894 million yen compared to the previous method.

Per share net income increased by 6.07 yen for the consolidated accounting period.

(Change in method of indication)

(Consolidated statements of income)

“Loss on valuation of investment securities” indicated as part of “Other” under “Extraordinary losses” for the previous consolidated fiscal period were recorded as an independent item beginning with the current consolidated fiscal period due to its increase in monetary importance.

“Loss on sale of property, plants and equipment”, which was recorded independently under “Extraordinary losses” for the previous consolidated fiscal period were recorded as part of “Other” beginning with the current consolidated fiscal period due to its decline in monetary importance.

Consolidated financial statements from the previous consolidated fiscal year have been revised to reflect this change.

As such, “Loss on sale of property, plants and equipment” 144 million yen and “Other” 761 million yen indicated under “Extraordinary Losses” on the consolidated statements of income for the previous consolidated accounting period was revised to “Loss on sale of property, plants and equipment” 100 million yen and “Other” 904 million yen.

(Change in accounting estimates)

Change in service life years

For the current research center and Tokachi Obihiro Plant scheduled for closure due to the construction of a new Meiji Co., Ltd. research center and new Tokachi Plant wing, we shortened the service life years for assets with no expected use following closure. This change was applied prospectively.

As a result of these changes, compared to previous methods, operating income, ordinary income, and income before income taxes and minority interests declined by 482 million yen, respectively.

Net income for the current consolidated fiscal period declined by 3.27 yen per share.

(Regarding business combination)

Current consolidated accounting period (from April 1, 2015 to March 31, 2016)

Revision details and amount in the event of important revisions to the initial amount allocated for acquisition costs

For stock acquisition related to Medreich Limited and its nine subsidiaries, which we acquired during the previous consolidated fiscal period, the allocation of acquisition costs had not been completed. The allocation of acquisition costs was completed during the current consolidated fiscal period, thus the following revisions were made to the goodwill amount.

Revised item	Goodwill revised amount	
Goodwill ( before revision )	23,996	million yen
Land	-1,908	million yen
Intangible assets	-7,474	million yen
Deferred tax liabilities	3,189	million yen
Revised total	-6,193	million yen
Goodwill ( revised )	17,803	million yen

(Segment Information, etc.)

#### 1. Outline of Reporting Segments

The reporting segments of the Meiji Group are the Group’s constituent units for which separate financial information is available and for which the Board of Directors regularly conducts examinations to determine the allocation of management resources and evaluate business performance.

The Meiji Group has operating subsidiaries organized based on products/services. Operating subsidiaries develop their business activities by formulating comprehensive strategies for Japan and overseas with respect to their products and services.

Consequently, the Meiji Group consists of segments based on operating subsidiaries, with two reporting segments: “Food” and “Pharmaceuticals.”

The “Food” business is handled by Meiji Co., Ltd., and the “Pharmaceuticals” business is handled by Meiji Seika Pharma Co., Ltd.

Each company’s main products are as follows.

Segment	Main Products
Food	Yogurt, drinking milk, beverages, cheese, butter, ice cream, confectionery, sports nutrition, infant formula, enteral formula, OTC drugs, sugar and corn sweeteners, etc.
Pharmaceuticals	Ethical pharmaceuticals, agricultural chemicals, veterinary drugs, etc.

2. Methods of Calculating Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment  
The accounting treatments for reporting segments are the same as those indicated in Significant Matters That Constitute the Basis for Preparation of Consolidated Financial Statements.

The profit of a reporting segment is the figure for operating income.

Inter-segment sales and transfers are mainly based on the price of third-party transactions, or on manufacturing costs.

3. Information on Net Sales, Income (Loss), Assets, Liabilities and Other Items for Each Reporting Segment  
The Previous Consolidated Fiscal Year (April 1, 2014 to March 31, 2015)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Consolidated Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	1,021,284	139,867	1,161,152	-	1,161,152
(2) Inter-segment Sales and Transfers	521	1,471	1,992	-1,992	-
Total	1,021,806	141,338	1,163,145	-1,992	1,161,152
Income by Segment	41,664	10,076	51,741	-198	51,543
Segment Assets	601,965	205,412	807,377	69,989	877,367
Other Items					
Depreciation	35,308	5,482	40,790	1,094	41,885
Investment in equity-method affiliates	3,999	-	3,999	-	3,999
Increase in property, plants and equipment/intangible assets	55,458	42,869	98,328	23	98,351

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative 198 million yen includes inter-segment eliminations of 66 million yen and a negative 264 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The segment assets adjustment of 69,989 million yen includes inter-segment elimination of a negative 163,412 million yen and corporate assets of 233,401 million yen not assigned to respective reporting segments. Major corporate assets include Company (the holding company) surplus investment assets (cash deposits), long-term investment capital (investment securities), and Company-held assets, etc.

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

The Current Consolidated Fiscal Year under Review (April 1, 2015 to March 31, 2016)

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Consolidated Statements of Income(Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	1,060,775	162,970	1,223,746	-	1,223,746
(2) Inter-segment Sales and Transfers	623	1,571	2,194	-2,194	-
Total	1,061,398	164,542	1,225,940	-2,194	1,223,746
Income by Segment	68,289	10,118	78,408	-626	77,781
Segment Assets	592,149	200,569	792,718	63,396	856,115
Other Items					
Depreciation	36,513	5,311	41,825	251	42,077
Investment in equity-method affiliates	4,357	7,102	11,460	-	11,460
Increase in property, plants and equipment/intangible assets	39,941	5,528	45,469	43	45,513

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative 626 million yen includes inter-segment eliminations of a negative 3 million yen and negative 622 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

The segment assets adjustment of 63,396 million yen includes inter-segment elimination of a negative 113,051 million yen and corporate assets of 176,448 million yen not assigned to respective reporting segments. Major corporate assets include Company (the holding company) surplus investment assets (cash deposits), long-term investment capital (investment securities), and Company-held assets, etc.

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

(Per Share Data)

	Previous Fiscal Year (ended March 31, 2015)	Fiscal Year under Review (ended March 31, 2016)
Net assets per share	2,515.26 yen	2,777.28 yen
Net income per share	209.79 yen	425.06 yen

(Notes)

1. Diluted net income per share is not given because there are no dilutive shares.

The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net income amounts for FYE March 2015 and FYE March 2016 reflect this stock split.

2. The basis for calculation of net income per share is as follows.

	Previous Fiscal Year (ended March 31, 2015)	Fiscal Year under Review (ended March 31, 2016)
Basis for calculating net income per share		
Net income attributable to shareholders of parent company	30,891 million yen	62,580 million yen
Amount not attributed to common shareholders	- million yen	- million yen
Net income attributable to shareholders of parent company of common shareholders	30,891 million yen	62,580 million yen
Average number of common stock outstanding during the year	147,249 thousands	147,227 thousands



(Significant Subsequent Events)

Not applicable.

## Consolidated Financial Results for Fiscal Year Ended March 31, 2016 - Supplementary Explanatory Data -

### Contents

<b>1. Consolidated Financial Results</b>	1
<b>2. Segment Information</b>	4
<b>3. Analysis of Operating Income</b>	7
<b>4. Consolidated Financial Positions</b>	8
<b>5. Capital Expenditures, Depreciation, R&amp;D Expenses</b>	9
<b>6. Financial Indicators, consolidated</b>	9
<b>7. Sales by Main Products</b>	10
<b>8. Other</b>	
1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies	12
2. List of New Products Under Development	12

# meiji

## Meiji Holdings Co., Ltd.

\*This document has been translated from the original Japanese as a guide for non-Japanese investors.

\*Unaudited figures are included in these materials for reference.

\*The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved.

\*Unless otherwise stated, figures for plan indicated in these materials are fiscal year initial targets announced on May 11, 2016.

\*Net sales of exports and foreign consolidated group companies (on page 11) are revised on February 5, 2016.

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

## 1. Consolidated Financial Results

### 1. Consolidated Operating Results

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%		
Net sales										
Cost of sales										
Gross profit										
Selling, general and administrative expenses										
Carriage and storage charges										
Sales promotion expenses										
Labor cost										
Operating income										
Ordinary income										
Net income attributable to owners of parent										

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
606.0	+2.3	645.0	+2.1	1,251.0	+2.2
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
32.5	-2.7	42.0	-5.4	74.5	-4.2
32.5	-8.6	41.7	-9.9	74.2	-9.3
23.5	-29.1	26.5	-10.0	50.0	-20.1

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Net sales	293.1	+7.1	49.7	592.3	+5.9	+0.4	914.3	+5.2	75.7	1,223.7	+5.4	+1.3
Cost of sales	188.5	+4.3	—	380.9	+3.0	—	584.4	+3.2	—	778.1	+2.7	—
Gross profit	104.6	+12.7	—	211.3	+11.5	—	329.8	+9.1	—	445.5	+10.5	—
Selling, general and administrative expenses	87.7	+6.9	—	177.9	+4.4	—	270.5	+4.4	—	367.7	+4.5	—
Carriage and storage charges	11.9	+18.2	—	24.1	+12.6	—	35.6	+11.4	—	46.9	+11.6	—
Sales promotion expenses	33.2	+8.9	—	67.5	+5.7	—	104.0	+4.6	—	142.4	+6.2	—
Labor cost	19.5	+3.1	—	39.0	+3.0	—	58.7	+3.4	—	78.4	+2.4	—
Operating income	16.8	+57.1	62.5	33.4	+76.0	+23.7	59.2	+38.1	89.2	77.7	+50.9	+17.0
Ordinary income	17.4	+55.7	60.2	35.5	+80.7	+22.6	62.4	+38.7	90.5	81.8	+52.7	+18.6
Net income attributable to owners of parent	22.2	+201.3	75.4	33.1	+163.0	+12.3	51.2	+73.2	95.7	62.5	+102.6	+17.0

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
592.3	+5.9	631.4	+4.9	1,223.7	+5.4
380.9	+3.0	397.2	+2.4	778.1	+2.7
211.3	+11.5	234.1	+9.5	445.5	+10.5
177.9	+4.4	189.7	+4.7	367.7	+4.5
24.1	+12.6	22.8	+10.5	46.9	+11.6
67.5	+5.7	74.8	+6.7	142.4	+6.2
39.0	+3.0	39.3	+1.9	78.4	+2.4
33.4	+76.0	44.3	+36.3	77.7	+50.9
35.5	+80.7	46.2	+36.5	81.8	+52.7
33.1	+163.0	29.4	+61.0	62.5	+102.6

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Net sales	273.6	-0.4	49.3	559.2	-0.7	+0.8	868.7	+0.7	76.1	1,161.1	+1.1	+1.8
Cost of sales	180.8	-0.0	—	369.7	-0.6	—	566.5	-0.1	—	757.7	+0.5	—
Gross profit	92.8	-1.0	—	189.5	-0.8	—	302.2	+2.3	—	403.3	+2.4	—
Selling, general and administrative expenses	82.1	-2.7	—	170.5	-2.6	—	259.2	-1.7	—	351.8	-1.6	—
Carriage and storage charges	10.0	-2.9	—	21.4	-1.2	—	32.0	-1.9	—	42.1	-2.3	—
Sales promotion expenses	30.5	-3.2	—	63.9	-5.1	—	99.4	-3.0	—	134.0	-4.2	—
Labor cost	19.0	+3.7	—	37.9	+3.1	—	56.8	+3.7	—	76.5	+4.0	—
Operating income	10.7	+14.4	74.6	18.9	+19.4	+31.8	42.9	+35.5	103.5	51.5	+41.2	+24.2
Ordinary income	11.2	+0.6	76.8	19.6	+9.9	+34.8	44.9	+30.9	105.9	53.5	+37.1	+26.1
Net income	7.3	+13.0	97.1	12.5	+28.7	+65.8	29.5	+55.4	111.6	30.8	+62.1	+16.6

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
559.2	-0.7	601.9	+2.9	1,161.1	+1.1
369.7	-0.6	388.0	+1.6	757.7	+0.5
189.5	-0.8	213.8	+5.3	403.3	+2.4
170.5	-2.6	181.2	-0.7	351.8	-1.6
21.4	-1.2	20.7	-3.5	42.1	-2.3
63.9	-5.1	70.1	-3.4	134.0	-4.2
37.9	+3.1	38.6	+5.0	76.5	+4.0
18.9	+19.4	32.5	+58.1	51.5	+41.2
19.6	+9.9	33.9	+60.0	53.5	+37.1
12.5	+28.7	18.2	+97.3	30.8	+62.1

## 2. Operating Results of Food Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Net sales					5.0			
Cost of sales								
Gross profit								
Selling, general and administrative expenses								
Carriage and storage charges								
Sales promotion expenses								
Labor cost								
Operating income								
Ordinary income								
Net income attributable to owners of parent								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
529.5	+2.4	543.5	-0.1	1,073.0	+1.1
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
31.0	+7.9	34.0	-14.0	65.0	-4.8
31.3	+2.2	34.1	-16.0	65.4	-8.1
23.0	+20.6	22.7	-17.1	45.7	-1.6

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Net sales	255.7	+3.7	49.7	517.1	+2.7	+0.4	795.9	+3.2	76.2	1,061.3	+3.9	+1.6
Cost of sales	170.9	+1.1	—	345.6	+0.1	—	528.4	+0.6	—	700.6	+0.7	—
Gross profit	84.7	+9.2	—	171.4	+8.4	—	267.5	+8.9	—	360.7	+10.6	—
Selling, general and administrative expenses	70.4	+3.9	—	142.7	+1.4	—	216.5	+1.5	—	292.4	+2.8	—
Carriage and storage charges	11.4	+18.0	—	23.2	+12.5	—	34.3	+11.2	—	45.1	+11.8	—
Sales promotion expenses	29.3	+7.1	—	59.5	+2.6	—	91.6	+2.4	—	124.7	+4.7	—
Labor cost	13.9	+0.7	—	27.7	+0.8	—	41.8	+1.5	—	55.7	+0.8	—
Operating income	14.3	+45.8	58.1	28.7	+64.9	+16.4	50.9	+57.5	94.3	68.2	+63.9	+26.5
Ordinary income	14.5	+46.6	54.6	30.6	+72.7	+14.7	53.0	+58.9	94.8	71.2	+63.6	+27.4
Net income attributable to owners of parent	9.0	+40.3	52.3	19.0	+75.9	+9.6	34.1	+59.8	97.0	46.4	+86.8	+32.0

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
517.1	+2.7	544.2	+5.0	1,061.3	+3.9
345.6	+0.1	355.0	+1.3	700.6	+0.7
171.4	+8.4	189.2	+12.7	360.7	+10.6
142.7	+1.4	149.7	+4.2	292.4	+2.8
23.2	+12.5	21.9	+11.0	45.1	+11.8
59.5	+2.6	65.1	+6.7	124.7	+4.7
27.7	+0.8	28.0	+0.7	55.7	+0.8
28.7	+64.9	39.5	+63.2	68.2	+63.9
30.6	+72.7	40.5	+57.4	71.2	+63.6
19.0	+75.9	27.3	+95.3	46.4	+86.8

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Net sales	246.7	+0.2	49.6	503.3	-0.2	+1.2	770.9	+0.5	76.2	1,021.8	+0.6	+1.0
Cost of sales	169.0	-0.1	—	345.1	-0.6	—	525.2	-0.3	—	695.6	-0.2	—
Gross profit	77.6	+0.9	—	158.1	+0.9	—	245.6	+2.4	—	326.1	+2.6	—
Selling, general and administrative expenses	67.8	-2.2	—	140.7	-1.8	—	213.3	-0.9	—	284.4	-1.8	—
Carriage and storage charges	9.7	-3.0	—	20.6	-1.3	—	30.8	-1.9	—	40.3	-2.6	—
Sales promotion expenses	27.4	-2.5	—	58.0	-3.5	—	89.5	-1.5	—	119.1	-3.2	—
Labor cost	13.8	+3.8	—	27.4	+2.8	—	41.2	+3.5	—	55.3	+3.4	—
Operating income	9.8	+29.0	73.5	17.4	+30.3	+30.1	32.3	+30.9	95.0	41.6	+47.8	+22.5
Ordinary income	9.9	+24.8	75.9	17.7	+27.6	+35.4	33.3	+31.2	97.5	43.5	+50.9	+27.2
Net income	6.4	+41.8	94.0	10.8	+47.5	+57.2	21.3	+57.9	104.2	24.8	+92.5	+21.3

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
503.3	-0.2	518.4	+1.4	1,021.8	+0.6
345.1	-0.6	350.5	+0.2	695.6	-0.2
158.1	+0.9	167.9	+4.2	326.1	+2.6
140.7	-1.8	143.6	-1.8	284.4	-1.8
20.6	-1.3	19.7	-3.8	40.3	-2.6
58.0	-3.5	61.0	-2.9	119.1	-3.2
27.4	+2.8	27.8	+4.0	55.3	+3.4
17.4	+30.3	24.2	+63.5	41.6	+47.8
17.7	+27.6	25.7	+72.6	43.5	+50.9
10.8	+47.5	14.0	+152.1	24.8	+92.5

### 3. Operating Results of Pharmaceuticals Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2			Q1-Q3			Full-year		
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan	
	%	%	%	%	%	%	%	%	%	%	
Net sales									5		
Cost of sales											
Gross profit											
Selling, general and administrative expenses											
Operating income											
Ordinary income											
Net income attributable to owners of parent											

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
77.3	+1.5	102.5	+16.0	179.8	+9.3
—	—	—	—	—	—
—	—	—	—	—	—
1.8	-63.6	8.2	+58.7	10.0	-1.2
1.2	-74.7	7.6	+27.2	8.8	-18.0
0.3	-88.0	4.1	+54.7	4.4	-14.6

FYE March 2016	Q1		Q1-Q2			Q1-Q3			Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%	%	%		
Net sales	37.6	+38.4	49.4	76.1	+34.1	-0.1	120.1	+20.7	72.2	164.5	+16.4	-1.1
Cost of sales	17.7	+48.6	—	36.0	+42.7	—	57.4	+34.8	—	79.3	+24.4	—
Gross profit	19.9	+30.4	—	40.0	+27.2	—	62.6	+10.2	—	85.2	+9.8	—
Selling, general and administrative expenses	17.3	+20.1	—	35.1	+17.4	—	53.7	+16.6	—	75.1	+11.2	—
Operating income	2.5	+209.3	114.9	4.9	+212.4	+120.2	8.8	-17.2	69.9	10.1	+0.4	-20.3
Ordinary income	2.5	+202.1	126.8	4.7	+212.5	+138.9	9.5	-12.5	71.8	10.7	+4.3	-19.3
Net income attributable to owners of parent	1.4	+139.8	228.0	2.5	+142.6	+301.9	5.7	-21.2	77.9	5.1	-5.0	-30.4

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
76.1	+34.1	88.3	+4.5	164.5	+16.4
36.0	+42.7	43.2	+12.4	79.3	+24.4
40.0	+27.2	45.1	-2.1	85.2	+9.8
35.1	+17.4	39.9	+6.3	75.1	+11.2
4.9	+212.4	5.1	-39.1	10.1	+0.4
4.7	+212.5	5.9	-31.8	10.7	+4.3
2.5	+142.6	2.6	-39.7	5.1	-5.0

FYE March 2015	Q1		Q1-Q2			Q1-Q3			Full-year			
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan	YoY change	vs. Full-year plan		
	%	%	%	%	%	%	%	%	%	%		
Net sales	27.2	-5.4	46.5	56.7	-4.8	-2.9	99.5	+2.4	75.6	141.3	+4.6	+7.4
Cost of sales	11.9	+0.5	—	25.2	+0.1	—	42.6	+3.6	—	63.7	+9.1	—
Gross profit	15.2	-9.6	—	31.5	-8.4	—	56.8	+1.6	—	77.6	+1.2	—
Selling, general and administrative expenses	14.4	-5.7	—	29.9	-6.3	—	46.1	-5.8	—	67.5	-1.2	—
Operating income	0.8	-47.6	83.5	1.5	-35.0	+58.4	10.7	+52.6	141.1	10.0	+20.6	+32.6
Ordinary income	0.8	-68.8	75.9	1.5	-57.4	+38.2	10.9	+31.6	140.0	10.2	+6.6	+31.8
Net income	0.5	-62.9	118.5	1.0	-51.7	+106.4	7.3	+43.2	143.5	5.4	-9.4	+6.9

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
56.7	-4.8	84.5	+12.0	141.3	+4.6
25.2	+0.1	38.4	+15.9	63.7	+9.1
31.5	-8.4	46.1	+9.0	77.6	+1.2
29.9	-6.3	37.6	+3.4	67.5	-1.2
1.5	-35.0	8.4	+43.5	10.0	+20.6
1.5	-57.4	8.7	+44.1	10.2	+6.6
1.0	-51.7	4.3	+14.0	5.4	-9.4

## 2. Segment Information

### 1. Food Segment

#### A. Net Sales

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Fresh and Fermented Dairy								
Processed Food								
Confectionery								
Nutritionals								
Other								
Elimination								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
254.5	+2.4	253.4	-3.7	508.0	-0.7
92.3	-6.2	87.1	-6.5	179.4	-6.4
70.4	+0.4	93.3	+3.3	163.7	+2.0
50.0	+1.5	47.1	+1.6	97.1	+1.5
180.0	+5.1	182.4	+2.5	362.5	+3.8
-117.9	—	-120.0	—	-238.0	—

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	125.0	+5.7	50.4	248.6	+4.1	+0.1	375.6	+4.5	77.9	511.7	+6.7	+6.1
Processed Food	48.1	+0.0	48.7	98.5	-1.3	-0.5	148.9	-1.7	77.3	191.6	-1.5	-0.5
Confectionery	34.9	-0.3	49.6	70.1	+0.2	-0.6	116.5	+0.1	73.4	160.4	+1.0	+1.2
Nutritionals	23.8	+24.2	49.4	49.3	+16.4	+2.1	75.1	+13.8	80.0	95.7	+12.2	+2.0
Other	83.5	-0.6	49.3	171.2	+1.5	+1.1	263.8	+3.4	74.1	349.3	+2.6	-1.9
Elimination	-59.8	—	—	-120.8	—	—	-184.1	—	—	-247.6	—	—

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
248.6	+4.1	263.0	+9.3	511.7	+6.7
98.5	-1.3	93.1	-1.7	191.6	-1.5
70.1	+0.2	90.3	+1.6	160.4	+1.0
49.3	+16.4	46.4	+8.0	95.7	+12.2
171.2	+1.5	178.1	+3.8	349.3	+2.6
-120.8	—	-126.8	—	-247.6	—

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	118.3	-2.6	—	238.7	-2.9	—	359.4	-1.4	—	479.4	-0.4	—
Processed Food	48.1	+0.9	—	99.7	-0.4	—	151.5	+0.1	—	194.5	-0.3	—
Confectionery	35.0	+8.1	—	70.0	+3.1	—	116.3	+2.6	—	158.9	+1.5	—
Nutritionals	19.2	-5.2	—	42.3	-1.6	—	66.0	-0.4	—	85.3	-1.3	—
Other	83.9	+3.6	—	168.7	+3.4	—	255.3	+3.4	—	340.3	+3.6	—
Elimination	-58.1	—	—	-116.3	—	—	-177.7	—	—	-236.9	—	—

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
%	%	%	%	%	%
238.7	-2.9	240.7	+2.2	479.4	-0.4
99.7	-0.4	94.7	-0.2	194.5	-0.3
70.0	+3.1	88.9	+0.3	158.9	+1.5
42.3	-1.6	43.0	-1.0	85.3	-1.3
168.7	+3.4	171.6	+3.9	340.3	+3.6
-116.3	—	-120.6	—	-236.9	—

Note1: As reference information for the Food segment, we have included results for each business category (simple calculation figures prior to elimination).

Note2: Eliminations within the Food segment include eliminations within each business category and between business categories. Also, general corporate expenses refer to expenses not allocated to any specific business.

B. Operating Incomes

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
	%	%	%	%	%	%	%	%
Fresh and Fermented Dairy								
Processed Food								
Confectionery								
Nutritionals								
Other								
Elimination and Corporate expenses								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
19.3	+9.1	20.7	-14.3	40.0	-4.4
3.7	+7.5	2.3	-8.6	6.0	+0.8
3.1	+18.0	9.7	-3.4	12.8	+1.1
6.4	+16.3	4.0	-2.2	10.5	+8.3
0.9	-1.7	2.1	+0.3	3.0	-0.4
-2.6		-4.9		-7.6	

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	9.2	+35.8	53.0	17.7	+34.1	+1.7	27.3	+33.1	82.8	41.9	+47.9	+27.0
Processed Food	1.4	+371.7	41.4	3.5	+114.3	+3.7	5.6	+81.5	101.4	6.0	+69.6	+7.5
Confectionery	1.7	-41.9	75.7	2.6	+0.9	+14.2	9.4	+25.1	98.7	12.7	+34.1	+33.4
Nutritionals	2.4	+173.4	60.5	5.5	+125.4	+3.5	9.1	+104.6	117.4	9.7	+111.0	+24.1
Other	0.4		104.1	1.1	+297.4	+14.9	2.7	+48.0	105.9	3.2	+69.3	+2.5
Elimination and Corporate expenses	-1.0			-1.8			-3.4			-5.3		

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
17.7	+34.1	24.2	+60.1	41.9	+47.9
3.5	+114.3	2.5	+31.3	6.0	+69.6
2.6	+0.9	10.0	+46.8	12.7	+34.1
5.5	+125.4	4.1	+94.6	9.7	+111.0
1.1	+297.4	2.0	+45.3	3.2	+69.3
-1.8		-3.4		-5.3	

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
	%	%	%	%	%	%	%	%				
Fresh and Fermented Dairy	6.7	-3.1		13.2	+16.9		20.5	+24.5		28.3	+25.2	
Processed Food	0.2	-41.4		1.6	-3.1		3.1	+14.9		3.5	+59.5	
Confectionery	3.0	+1,929.5		2.6	+566.8		7.5	+48.1		9.5	+67.1	
Nutritionals	0.9	+133.2		2.4	+89.2		4.4	+40.7		4.6	+66.3	
Other	-0.2			0.0	-8.8		0.4			0.4		
Elimination and Corporate expenses	-0.9			-2.5			-3.8			-4.7		

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
13.2	+16.9	15.1	+33.5	28.3	+25.2
1.6	-3.1	1.9	+256.2	3.5	+59.5
2.6	+566.8	6.8	+29.8	9.5	+67.1
2.4	+89.2	2.1	+46.2	4.6	+66.3
0.0	-8.8	0.3		0.4	
-2.5		-2.2		-4.7	

Note1: As reference information for the Food segment, we have included results for each business category (simple calculation figures prior to elimination).

Note2: Eliminations within the Food segment include eliminations within each business category and between business categories. Also, general corporate expenses refer to expenses not allocated to any specific business.

2. Pharmaceuticals Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Ethical Pharmaceuticals	%	%	%	%	%	%	%	%
Agricultural Chemicals and Veterinary Drugs								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
70.0	+1.2	87.5	+17.4	157.6	+9.6
7.3	+5.8	14.9	+8.1	22.2	+7.3

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Ethical Pharmaceuticals	34.0	+38.7	49.5	69.2	+35.8	+0.5	109.4	+21.7	75.6	143.7	+18.0	-0.7
Agricultural Chemicals and Veterinary Drugs	3.6	+35.8	49.2	6.8	+19.5	-5.9	10.7	+11.5	49.6	20.7	+6.6	-3.9

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
69.2	+35.8	74.5	+5.2	143.7	+18.0
6.8	+19.5	13.8	+1.2	20.7	+6.6

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Ethical Pharmaceuticals	24.5	-6.4	—	51.0	-3.1	—	89.8	+4.1	—	121.8	+7.3	—
Agricultural Chemicals and Veterinary Drugs	2.6	+3.4	—	5.7	-17.6	—	9.6	-11.4	—	19.4	-9.7	—

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
51.0	-3.1	70.8	+16.3	121.8	+7.3
5.7	-17.6	13.7	-5.9	19.4	-9.7




### 3. Analysis of Operating Income

#### 1. Results

(Billions of yen)

	Q1				Q1-Q2				Q1-Q3				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2015	10.7	9.8	0.8	0.1	18.9	17.4	1.5	0.0	42.9	32.3	10.7	0.0	51.5	41.6	10.0	Δ0.1
Due to increased/decreased sales	+5.6	+3.7	+1.9	—	+6.2	+4.1	+2.1	—	+9.1	+6.5	+2.6	—	+14.2	+11.6	+2.6	—
Costs of goods sold increase	-4.1	-4.1	0.0	—	-5.4	-5.4	0.0	—	-6.2	-6.2	0.0	—	-6.7	-6.7	0.0	—
Cost reduction	+3.9	+3.5	+0.4	—	+8.5	+7.6	+0.9	—	+11.9	+10.9	+1.0	—	+16.2	+15.1	+1.1	—
Changes in other SG&A expenses	-0.2	+0.6	-0.8	—	+2.2	+2.6	-0.4	—	+2.2	+3.7	-1.5	—	+1.0	+1.7	-0.7	—
Other (incl. change in results of subsidiaries)	+0.9	+0.8	+0.2	-0.1	+3.0	+2.4	+0.8	-0.2	-0.7	+3.7	-3.9	-0.4	+1.5	+4.9	-2.9	-0.5
Total change	+6.1	+4.5	+1.7	-0.1	+14.5	+11.3	+3.4	-0.2	+16.3	+18.6	-1.8	-0.4	+26.2	+26.6	+0.1	-0.5
Results -- FYE March 2016	16.8	14.3	2.5	0.0	33.4	28.7	4.9	-0.2	59.2	50.9	8.8	-0.4	77.7	68.2	10.1	-0.6



(Breakdown)

\*1: [Food] “Cost reduction” includes price revision of products, net content reduction of products, decrease in volume of price-revised products, or increase in sales promotion expenses for price-revised products.  
 Fresh and Fermented Dairy business: +8.2  
 Processed Food business: +5.0

[Pharma] Cost of sales reduction: +1.1

#### 2. Plan -- FYE March 2017

(Billions of yen)

	H1 (Q1-Q2)				H2 (Q3-Q4)				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2016	33.4	28.7	4.9	Δ0.2	44.3	39.5	5.1	-0.4	77.7	68.2	10.1	-0.6
Due to increased/decreased sales	+4.6	+1.9	+2.7	—	+6.6	-1.5	+8.1	—	+11.2	+0.4	+10.8	—
Impact of drug price revision	-4.2	—	-4.2	—	-5.0	—	-5.0	—	-9.2	—	-9.2	—
Changes in costs of goods sold	+1.1	+1.1	0.0	—	-0.5	-0.5	0.0	—	+0.6	+0.6	0.0	—
Changes in other SG&A expenses	-2.1	-0.4	-1.7	—	-2.8	-1.9	-0.9	—	-4.9	-2.3	-2.6	—
Other (incl. change in results of subsidiaries)	-0.3	-0.3	+0.1	-0.1	-0.6	-1.6	+0.8	+0.2	-0.9	-1.9	+0.9	+0.1
Total change	-0.9	+2.3	-3.1	-0.1	-2.3	-5.5	+3.0	+0.2	-3.2	-3.2	-0.1	+0.1
Plan -- FYE March 2017	32.5	31.0	1.8	-0.3	42.0	34.0	8.2	-0.2	74.5	65.0	10.0	-0.5

#### 4. Consolidated Financial Positions

(Billions of yen)

FYE March 2016	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31		
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end	
Total assets	860.6	-1.9%	855.8	-2.4%	899.8	+2.6%	856.1	Δ2.4	
Current assets	350.3	-0.5	354.1	+0.6	385.3	+9.5	362.9	+3.1	
Fixed assets	510.2	-2.9	501.7	-4.5	514.5	-2.1	493.1	Δ6.1	
Total liabilities	461.1	-7.2	448.6	-9.7	474.2	-4.6	436.9	Δ12.1	
Current liabilities	261.2	-12.5	271.0	-9.2	308.6	+3.4	276.6	Δ7.3	
Long-term liabilities	199.8	+0.7	177.6	-10.5	165.6	-16.6	160.2	Δ19.3	
Total net assets	399.4	+5.0	407.1	+7.1	425.5	+11.9	419.1	+10.2	
Shareholders' equity	360.2	+5.2	371.2	+8.4	385.2	+12.5	396.6	+15.8	
Reference	Consolidated interest bearing debt	200.3	-9.5	179.6	-18.9	175.5	-20.7	147.8	Δ33.3
	Food segment assets	601.1	-0.1	610.4	+1.4	634.7	+5.4	592.1	Δ1.6
	Pharmaceuticals segment assets	200.3	-2.5	194.4	-5.3	205.1	-0.1	200.5	Δ2.4

FYE March 2015	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31		
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end	
Total assets	782.7	-1.4%	793.7	+1.5%	849.2	+3.3%	877.3	+12.6	
Current assets	326.6	-4.4	333.5	+2.7	373.3	+4.8	352.0	+7.0	
Fixed assets	456.0	+0.8	460.2	+0.7	475.8	+2.1	525.3	+16.6	
Total liabilities	449.4	-3.5	453.1	+1.1	485.9	+1.1	497.0	+10.1	
Current liabilities	257.3	-15.7	259.8	-5.7	289.7	-5.3	298.5	+14.2	
Long-term liabilities	192.0	+19.6	193.2	+12.1	196.2	+12.3	198.4	+4.5	
Total net assets	333.3	+1.5	340.6	+2.0	363.2	+6.3	380.3	+15.9	
Shareholders' equity	321.9	+4.2	327.1	+4.8	341.1	+7.1	342.4	+7.6	
Reference	Consolidated interest bearing debt	207.9	-6.8	196.6	-4.4	200.9	-5.0	221.4	+11.6
	Food segment assets	569.7	-3.1	583.4	+1.0	617.4	+2.5	601.9	+6.7
	Pharmaceuticals segment assets	149.0	+3.2	147.9	+2.3	167.1	+7.9	205.4	+33.1

## 5. Capital Expenditures, Depreciation, R&D Expenses

(Billions of yen)

	FYE March 2014		FYE March 2015		FYE March 2016		FYE March 2017 -- Plan	
	H1	Full-year	H1	Full-year	H1 (Q1-Q2)	Full-year	H1 (Q1-Q2)	Full-year
Capital expenditures	21.8	47.0	28.4	64.3	24.1	42.3	20.5	46.7
Food segment	18.8	41.5	24.9	55.8	21.2	36.5	16.0	39.4
Pharmaceutical segment	2.9	5.4	3.5	8.5	2.8	5.7	4.5	7.2
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Depreciation and amortization	19.8	40.9	19.9	41.8	19.7	42.0	20.9	42.7
Food segment	16.6	34.3	16.9	35.3	17.3	36.5	17.8	36.5
Pharmaceutical segment	2.5	5.4	2.4	5.4	2.2	5.3	3.0	6.0
Corporate or elimination	0.6	1.1	0.5	1.0	0.1	0.2	0.1	0.2
R&D expenses	12.3	26.0	11.9	26.1	12.9	27.3	12.7	26.5
Food segment	5.6	11.3	6.1	12.5	6.4	12.6	6.4	12.4
Pharmaceutical segment	6.7	14.7	5.7	13.5	6.5	14.6	6.3	14.1
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

## 6. Financial Indicators, consolidated

	FYE March 2013	FYE March 2014	FYE March 2015	FYE March 2016
	Full-year	Full-year	Full-year	Full-year
Net sales	1,126.5 billion yen	1,148.0 billion yen	1,161.1 billion yen	1,223.7 billion yen
Operating income	25.8 billion yen	36.4 billion yen	51.5 billion yen	77.7 billion yen
Operating income ratio	2.3 %	3.2 %	4.4 %	6.4 %
EBITDA	66.8 billion yen	77.6 billion yen	94.0 billion yen	121.6 billion yen
EBITDA margin	5.9 %	6.8 %	8.1 %	9.9 %
Net income attributable to shareholders of parent company	16.6 billion yen	19.0 billion yen	30.8 billion yen	62.5 billion yen
Net income ratio	1.5 %	1.7 %	2.7 %	5.1 %
Total assets	785.5 billion yen	779.4 billion yen	877.3 billion yen	856.1 billion yen
Interest bearing debt	205.3 billion yen	198.3 billion yen	221.4 billion yen	147.8 billion yen
Shareholders' equity	313.3 billion yen	320.4 billion yen	370.3 billion yen	408.8 billion yen
Shareholders' equity ratio	39.9 %	41.1 %	42.2 %	47.8 %
Debt/Equity ratio	0.7 %	0.6 %	0.6 %	0.4 %
ROA	3.8 %	5.0 %	6.5 %	9.4 %
ROE	5.5 %	6.0 %	8.9 %	16.1 %
Cash flows from operating activities	50.6 billion yen	63.8 billion yen	86.4 billion yen	105.1 billion yen
Cash flows from investing activities	-39.5 billion yen	-47.2 billion yen	-92.8 billion yen	-9.8 billion yen
Free cash flows	11.1 billion yen	16.5 billion yen	-6.3 billion yen	95.3 billion yen
Net income per share	112.99 yen	129.40 yen	209.79 yen	425.06 yen
Net assets per share	2,127.28 yen	2,175.98 yen	2,515.26 yen	2,777.28 yen
Cash flow per share	390.07 yen	407.55 yen	494.24 yen	710.89 yen
Cash dividends per share	40.00 yen	40.00 yen	50.00 yen	90.00 yen
Dividend payout ratio	35.4 %	30.9 %	23.8 %	21.2 %
Price/Earnings ratio--PER	19.3 times	25.2 times	34.9 times	21.3 times
Price/Book value ratio--PBR	1.0 times	1.5 times	2.9 times	3.3 times
Price/Cash flow ratio--PCFR	5.6 times	8.0 times	14.8 times	12.7 times

Note: The above figures per share are calculated by retroactively applying the number of shares resulting from the stock split conducted on October 1, 2015.

(Note) Op. income + Depreciation and amortization

(Note) Ordinary income/Average net assets

(Note) Net income attributable to shareholders of parent company/Average shareholders' equity

(Note) Cash flows from operating activities + Cash flows from investing activities

(Note) Net income attributable to shareholders of parent company / (Number of shares outstanding - Number of treasury stock)

(Note) (Total net assets - Noncontrolling interests) / (Number of shares outstanding - Number of treasury stock)

(Note) (Net income attributable to shareholders of parent company + Depreciation and Amortization) / (Number of shares outstanding - Number of treasury stock)

(Note) Year-end stock price/Net income per share

(Note) Year-end stock price/Net assets per share

(Note) Year-end stock price/Cash flow per share

## 7. Sales by Main Products

### 1. Food Segment (Non-consolidated)

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
	%	%	%	%	%	%	%	%
Yogurt								
Meiji Bulgaria Yogurt								
Probiotic yogurts								
Drinking milk								
Meiji Oishii Gyunyu								
Cheese								
Meiji Hokkaido Tokachi series								
Ice cream								
Chocolate								
Nutritional products								
Sports nutrition								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
42.8	+0.1	39.9	-1.0	82.8	-0.5
40.0	+2.7	37.5	+1.2	77.6	+2.0
48.2	+5.8	59.7	-2.3	108.0	+1.2
54.5	-2.8	49.6	-6.1	104.1	-4.4
29.5	-1.6	26.1	-4.8	55.6	-3.1
16.6	+2.1	18.3	-0.5	35.0	+0.7
5.9	+1.8	6.8	+1.8	12.8	+1.8
29.3	+1.3	16.9	-3.7	46.2	-0.6
39.2	+3.0	58.8	+2.2	98.0	+2.5
25.6	+3.7	26.5	+3.6	52.1	+3.7
10.0	+15.2	8.2	+10.5	18.3	+13.1

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
	%	%	%	%	%	%	%	%				
Yogurt	21.4	+5.2	50.7	42.8	+6.4	+1.3	62.6	+6.1	78.8	83.1	+6.4	+4.6
Meiji Bulgaria Yogurt	19.4	+4.6	50.7	39.0	+6.0	+1.6	57.2	+6.0	79.8	76.1	+6.4	+6.2
Probiotic yogurts	23.5	+22.7	51.6	45.6	+17.0	+0.0	71.1	+15.6	72.9	106.7	+22.4	+9.5
Drinking milk	27.6	+1.4	49.8	56.1	+1.3	+1.3	83.3	+1.2	80.2	108.9	+1.5	+4.8
Meiji Oishii Gyunyu	14.3	+5.6	49.8	29.9	+4.6	+4.0	44.0	+4.4	79.3	57.4	+4.2	+3.5
Cheese	8.2	+1.3	50.5	16.3	+1.0	+0.1	26.2	+2.7	77.7	34.8	+3.1	+3.0
Meiji Hokkaido Tokachi series	3.0	+12.8	50.5	5.8	+10.9	-1.3	9.6	+9.1	81.8	12.6	+8.2	+7.2
Ice cream <sup>(Note1)</sup>	13.2	+6.9	44.8	28.9	+4.0	-2.1	38.2	+5.0	83.5	46.5	+5.3	+1.4
Chocolate	18.8	+2.2	49.6	38.0	+1.6	+0.0	67.4	+1.6	72.7	95.6	+3.0	+3.0
Nutritional products <sup>(Note2)</sup>	12.0	+15.4	49.6	24.6	+11.2	+1.4	38.6	+9.2	78.1	50.3	+8.7	+1.7
Sports nutrition	4.3	+48.5	51.9	8.7	+32.4	+4.3	12.7	+33.3	85.9	16.2	+30.4	+9.3

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
42.8	+6.4	40.3	+6.3	83.1	+6.4
39.0	+6.0	37.1	+6.7	76.1	+6.4
45.6	+17.0	61.1	+26.7	106.7	+22.4
56.1	+1.3	52.8	+1.7	108.9	+1.5
29.9	+4.6	27.4	+3.8	57.4	+4.2
16.3	+1.0	18.4	+5.0	34.8	+3.1
5.8	+10.9	6.7	+5.9	12.6	+8.2
28.9	+4.0	17.5	+7.5	46.5	+5.3
38.0	+1.6	57.5	+3.9	95.6	+3.0
24.6	+11.2	25.6	+6.4	50.3	+8.7
8.7	+32.4	7.5	+28.2	16.2	+30.4

FYE March 2015	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
	%	%	%	%	%	%	%	%				
Yogurt	20.3	-6.7	45.1	40.2	-5.8	-11.1	59.0	-3.8	75.3	78.2	-2.6	-0.3
Meiji Bulgaria Yogurt	18.6	-6.2	47.0	36.8	-5.4	-7.2	54.0	-3.3	75.7	71.6	-2.1	+0.3
Probiotic yogurts	19.1	+15.2	52.1	39.0	+19.3	+6.0	61.5	+19.6	74.1	87.2	+17.4	+5.1
Drinking milk	27.2	+0.3	47.8	55.4	-0.6	-2.8	82.3	-0.7	83.6	107.3	-0.3	+9.0
Meiji Oishii Gyunyu	13.6	+5.8	50.1	28.6	+4.7	+5.5	42.1	+5.0	80.1	55.0	+5.7	+4.6
Cheese	8.1	+8.7	52.2	16.1	+7.4	+3.8	25.6	+7.6	79.0	33.7	+6.3	+4.2
Meiji Hokkaido Tokachi series	2.6	+8.6	49.7	5.3	+6.3	-1.3	8.8	+11.2	79.3	11.7	+10.2	+4.8
Ice cream <sup>(Note1)</sup>	12.3	+5.1	—	27.8	+0.2	—	36.4	+0.7	—	44.1	+2.2	—
Chocolate	18.4	+9.5	50.3	37.4	+6.8	+2.1	66.4	+6.1	73.2	92.8	+4.5	+2.3
Nutritional products <sup>(Note2)</sup>	10.4	+3.0	—	22.2	+6.5	—	35.3	+6.0	—	46.3	+5.7	—
Sports nutrition	2.9	-22.6	40.8	6.5	-12.5	-8.2	9.5	-8.7	76.7	12.4	-10.5	-0.4

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
40.2	-5.8	37.9	+1.1	78.2	-2.6
36.8	-5.4	34.8	+1.7	71.6	-2.1
39.0	+19.3	48.2	+15.8	87.2	+17.4
55.4	-0.6	51.9	+0.0	107.3	-0.3
28.6	+4.7	26.4	+6.9	55.0	+5.7
16.1	+7.4	17.5	+5.3	33.7	+6.3
5.3	+6.3	6.3	+13.7	11.7	+10.2
27.8	+0.2	16.3	+5.6	44.1	+2.2
37.4	+6.8	55.3	+3.0	92.8	+4.5
22.2	+6.5	24.1	+4.9	46.3	+5.7
6.5	-12.5	5.8	-8.2	12.4	-10.5

Note1: Beginning with the first three months of FYE March 2016, the ice cream business disclosure method was changed to reflect the total for both consumer and commercial sales.

Results from FYE March 2015 were adjusted retroactively to reflect this method.

Note2: Nutritional products includes infant formula and enteral formula.

2. Pharmaceuticals Segment (Non-consolidated)

(Billions of yen)

FYE March 2017		Q1		Q1-Q2		Q1-Q3		Full-year	
		YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
		%	%	%	%	%	%	%	%
Ethical pharma ceuticals	Total brand name drugs								
	MEIACT								
	ORAPENEM								
	REFLEX								
	Total generic drugs								
	AMLODIPINE								
	DONEPEZIL								
(By field)	Total infectious diseases*								
	Total CNS disorders*								
Export	MEIACT								
Agric.	ORYZEMATE								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
25.8	+1.2	33.3	+20.5	59.2	+11.2
4.7	-22.2	5.1	-29.6	9.8	-26.2
0.9	+0.3	1.6	+15.8	2.5	+9.5
9.4	+1.8	10.9	+11.6	20.3	+6.8
21.4	+3.4	27.5	+23.4	48.9	+13.8
2.6	-3.4	3.0	+8.9	5.7	+2.8
1.8	+0.4	2.1	+19.8	3.9	+10.0
16.9	-12.2	19.8	-7.5	36.8	-9.7
15.9	-0.6	18.3	+9.9	34.3	+4.8
1.0	-36.1	1.1	+40.2	2.1	-9.5
0.4	+0.4	7.2	+17.7	7.6	+16.4

FYE March 2016		Q1		Q1-Q2		Q1-Q3		Full-year					
		YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
		%	%	%	%	%	%	%	%				
Ethical pharma ceuticals	Total brand name drugs	12.7	+12.5	49.7	25.5	+9.6	-0.6	40.7	+4.7	75.6	53.2	+3.9	-1.4
	MEIACT	3.1	+0.4	52.6	6.1	+3.1	+2.4	10.3	-1.4	80.3	13.4	-2.4	+3.6
	ORAPENEM	0.5	+43.1	49.3	0.9	+31.0	-10.7	1.7	+16.5	71.3	2.3	+12.5	-4.9
	REFLEX	4.4	+50.1	48.2	9.2	+30.7	+0.4	14.3	+21.0	73.3	19.0	+20.5	-2.7
	Total generic drugs	10.1	+15.6	46.4	20.7	+16.9	-5.4	32.8	+15.8	74.4	43.0	+14.3	-2.5
	AMLODIPINE	1.3	+12.2	48.2	2.7	+13.1	-2.0	4.3	+12.2	76.2	5.5	+8.6	-1.8
	DONEPEZIL	0.8	+11.2	39.6	1.7	+10.0	-18.5	2.7	+9.8	65.2	3.5	+6.1	-17.4
(By field)	Total infectious diseases*	9.6	+8.0	51.8	19.3	+9.0	+3.2	31.4	+5.1	78.6	40.7	+4.3	+2.0
	Total CNS disorders*	7.8	+23.8	47.7	16.0	+16.7	-2.1	25.0	+12.8	73.9	32.8	+12.2	-3.3
Export	MEIACT	0.8	+162.7	127.3	1.5	+111.6	+134.3	2.2	+77.7	77.5	2.4	+82.3	-15.7
Agric.	ORYZEMATE	0.3	+62.7	74.1	0.4	+50.6	-9.3	1.2	+39.9	16.7	6.6	+5.1	-13.7

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
25.5	+9.6	27.6	-0.8	53.2	+3.9
6.1	+3.1	7.2	-6.7	13.4	-2.4
0.9	+31.0	1.3	+2.6	2.3	+12.5
9.2	+30.7	9.7	+12.2	19.0	+20.5
20.7	+16.9	22.3	+11.9	43.0	+14.3
2.7	+13.1	2.8	+4.6	5.5	+8.6
1.7	+10.0	1.7	+2.4	3.5	+6.1
19.3	+9.0	21.4	+0.5	40.7	+4.3
16.0	+16.7	16.7	+8.1	32.8	+12.2
1.5	+111.6	0.8	+44.7	2.4	+82.3
0.4	+50.6	6.1	+2.6	6.6	+5.1

FYE March 2015		Q1		Q1-Q2		Q1-Q3		Full-year					
		YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
		%	%	%	%	%	%	%	%				
Ethical pharma ceuticals	Total brand name drugs	11.3	-20.2	49.3	23.3	-14.1	+1.1	38.9	-12.5	76.0	51.2	-13.0	-0.1
	MEIACT	3.1	-22.2	52.4	5.9	-19.5	-0.7	10.5	-17.6	78.5	13.7	-15.7	+2.3
	ORAPENEM	0.3	-34.9	27.8	0.7	-21.0	-45.0	1.4	-9.4	65.6	2.0	-10.6	-6.3
	REFLEX	2.9	-21.5	42.2	7.0	-6.8	+0.9	11.8	-2.3	70.8	15.7	-5.6	-5.7
	Total generic drugs	8.7	+15.4	50.6	17.7	+17.1	+2.1	28.3	+15.5	76.2	37.6	+17.1	+1.2
	AMLODIPINE	1.2	+16.5	53.3	2.4	+18.4	+7.4	3.8	+17.8	75.0	5.1	+18.2	-0.2
	DONEPEZIL	0.7	+38.7	39.2	1.6	+37.9	-18.6	2.5	+28.5	65.3	3.8	+27.2	-14.4
(By field)	Total infectious diseases*	8.9	-14.7	51.2	17.7	-10.7	+1.0	29.9	-10.1	79.2	39.0	-9.3	+3.5
	Total CNS disorders*	6.3	-13.2	46.5	13.7	-5.1	+1.2	22.2	-3.5	73.1	29.2	-4.7	-3.9
Export	MEIACT	0.3	+135.5	31.4	0.7	+60.5	-28.3	1.2	+56.9	76.7	1.3	-17.5	-18.8
Agric.	ORYZEMATE	0.2	-54.1	56.0	0.3	-63.0	-26.0	0.9	-51.6	13.6	6.2	-17.6	-6.1

Results -- FYE March 2015					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
23.3	-14.1	27.9	-12.2	51.2	-13.0
5.9	-19.5	7.7	-12.6	13.7	-15.7
0.7	-21.0	1.3	-3.9	2.0	-10.6
7.0	-6.8	8.7	-4.6	15.7	-5.6
17.7	+17.1	19.9	+17.1	37.6	+17.1
2.4	+18.4	2.6	+17.9	5.1	+18.2
1.6	+37.9	1.7	+18.4	3.3	+27.2
17.7	-10.7	21.3	-8.1	39.0	-9.3
13.7	-5.1	15.4	-4.4	29.2	-4.7
0.7	+60.5	0.5	-49.1	1.3	-17.5
0.3	-63.0	5.9	+11.8	6.2	-17.6

Note: Total for brand name and generic drugs in the infectious diseases and the CNS disorders fields

## 8. Other

### 1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
Food segment	%	%	%	%	%	%	%	%
Pharmaceuticals segment								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
20.4	+16.0	24.3	+17.6	44.8	+16.9
21.9	+5.3	24.1	+14.4	46.1	+9.9

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
Food segment	7.8	+21.4	45.4	17.6	+34.6	+1.0	28.3	+39.6	73.0	38.3	+30.4	-1.3
Pharmaceuticals segment	10.7	+176.2	52.2	20.8	+150.9	+0.9	30.3	+129.6	72.4	41.9	+75.1	+0.2

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
17.6	+34.6	20.7	+27.0	38.3	+30.4
20.8	+150.9	21.0	+34.8	41.9	+75.1

FYE March 2015	Results	
	Full-year	YoY Change
Food segment	29.4	+1.1
Pharmaceuticals segment	23.9	+38.3

Note 1: Net sales for the parent company export business and net sales (after elimination) from international subsidiaries subject to the scope of consolidation are indicated as above reference information.

Note 2: The above figures for Food segment are revised on February 5, 2016.

### 2. List of New Products Under Development

Stage	Name	Type	Efficacy Classification	Notes
Approved	Sycrest ME2136 (Asenapine)	Sublingual tablet	Antipsychotic drug	Approved on March 28, 2016 In-license: Merck Sharp&Dohme B.V. (Netherlands)
Phase III	Depromel SME3110 (Fluvoxamine)	Oral	Pediatric OCD (Selective serotonin reuptake inhibitor (SSRI)) (expanded indication)	Co-development: AbbVie G.K.
	ME2112 (Ziprasidone)	Oral	Antipsychotic drug	In-license: RaQualia Pharma Inc.
Phase II/III	ME2125 (Safinamide)	Oral	Anti-Parkinson's disease	In-license: Newron Pharmaceutical S.p.A. (Italy)
Phase II	REFLEX Org3770 (Mirtazapine)	Oral	Fibromyalgia treatment (expanded indication)	In-license: MSD K.K.
Phase II (Overseas)	ME1111	Topical	Antionychomycosis drug	Meiji Seika Pharma Co., Ltd.
Phase I	DMB-3111 (Trastuzumab biosimilar)	Injection	Breast cancer, Gastric cancer	Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)
Phase I (Overseas)	ME1100 (Arbekacin inhalation)	Inhalation	Hospital acquired bacterial pneumonia/Ventilator associated bacterial pneumonia	Meiji Seika Pharma Co., Ltd.
	OP0595	Injection	$\beta$ -lactamase inhibitor	Meiji Seika Pharma Co., Ltd. Licensed out to F. Hoffman-La Roche Ltd (Switzerland)